Home

Andrew C. Jackson

CIK 1636738 · Chief Financial Officer · last filed 2026-08-19

Andrew C. Jackson is a Chief Financial Officer who has filed 15 SEC Form 4 insider transactions across 4 companies since 2019. The most recent filing, for CLDI, was dated Aug 19, 2026. Across all open-market trades the lifetime net is −$9.7K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $193 across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$193

Companies

4

Total Filings

15

Lifetime Open-Market Net

-$9.7K

Filer Profile

Reported Address
11988 EL CAMINO REAL STE. 650
SAN DIEGO, CA 92130
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CLDI Chief Financial Officer 156 $1.24 $193 $5.0K 3 2026-08-19
Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted Chief Financial Officer — $0.01 — $0 1 2024-06-20
BTX Chief Financial Officer — $8.87 — $0 1 2022-06-06
Catheter Precision, Inc. (RMED) Delisted CFO 434 $0.59 $258 -$14.7K 10 2022-05-24

Recent Filings

15 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-19 CLDI Grant (A) — $0 EDGAR
2025-09-05 CLDI Grant (A) — $0 EDGAR
2025-08-25 CLDI Buy (P) +2,500 $5.0K EDGAR
2024-06-20 Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted Grant (A) — $0 EDGAR
2022-06-06 BTX Grant (A) — $0 EDGAR
2022-05-24 Catheter Precision, Inc. (RMED) Delisted Tax (F) −1,361 -$410 EDGAR
2021-11-24 Catheter Precision, Inc. (RMED) Delisted Mixed −14,443 -$7.0K EDGAR
2020-11-24 Catheter Precision, Inc. (RMED) Delisted Grant (A) +200 $1.1K EDGAR
2020-11-19 Catheter Precision, Inc. (RMED) Delisted Grant (A) +35,276 $0 EDGAR
2020-08-05 Catheter Precision, Inc. (RMED) Delisted Buy (P) +10,000 $3.5K EDGAR
Showing 1–10 of 15
Page 1 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.